medicine.Bleeding disorders.(dr.sabir) (new powerpoint)
-
Upload
student -
Category
Health & Medicine
-
view
7.383 -
download
0
Transcript of medicine.Bleeding disorders.(dr.sabir) (new powerpoint)
![Page 1: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/1.jpg)
Bleeding Bleeding DisordersDisorders
By Dr. Sabir M. AmeenBy Dr. Sabir M. Ameen
![Page 2: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/2.jpg)
HistoryHistory1 .Site of bleeding:
*Muscle & joint bleeds indicate a coagulation defect
*purpura, prolonged bleeding from superficial cuts, epistaxis, GI bleeding, menorrhagia, indicate PLT disorder, thrombocytopenia or vW disease
![Page 3: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/3.jpg)
HistoryHistory2 .Duration: congenital or acquired
3 .Precipitating cause: if spontaneous indicate severe defect
4 .surgery: dental extraction, tonsillectomy, circumcision. Bleeding immediately after surgery indicate defective PLT plug formation. Bleeding after some hours indicate failure of PLT plug stabilisation by fibrin due to coagulation defect.
![Page 4: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/4.jpg)
HistoryHistory5 .Family history :
*Hereditary or acquired *Negative history does not exclude a
hereditary cause, as e.g: about 1/3 of cases of hemophilia have negative family history (mutations).
6 .Systemic disease :
Hepatic or renal failureCT disease
![Page 5: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/5.jpg)
historyhistory7 .Drugs: almost any drug can
potentially produce bleeding( cytotoxics. NSAIDs…etc)
![Page 6: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/6.jpg)
ExaminationExaminationLook for: 1. anemia: BM failure, leukemia
2 .purpura, bruises, bleeding in mouth3 .Telangiectasia of lips (HHT)
4 .LN enlargement: leukemia, viral ( ITP)5 .Stigmata of chronic liver disease: spider
nevi, clubbing, palmar erythema…etc6 .Fundal examination
![Page 7: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/7.jpg)
Clinical Features of Bleeding DisordersClinical Features of Bleeding Disorders
Platelet Coagulation disorders fac disorders
Site of bleeding Skin Deep in soft tis. Mucous membranes (joints, musc)
Petechiae Yes No
Ecchymoses (“bruises”) Small, superficial Large, deep
Hemarthrosis / muscle bleeding Extremely rare Common
Bleeding after cuts & scratches Yes No
Bleeding after surgery or trauma Immediate, Delayed1-2 d usually mild often severe
![Page 8: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/8.jpg)
Platelet CoagulationPlatelet Coagulation
Petechiae, Purpura Hematoma, Joint bl.
![Page 9: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/9.jpg)
PetechiaePetechiae
Do not blanch with Do not blanch with pressurepressure
(cf. angiomas) (cf. angiomas)Not palpableNot palpable
(cf. vasculitis) (cf. vasculitis)
(typical of platelet disorders)
![Page 10: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/10.jpg)
HemarthrosisHemarthrosis
![Page 11: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/11.jpg)
HematomaHematoma
![Page 12: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/12.jpg)
PetechiaePetechiae
![Page 13: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/13.jpg)
PurpuraPurpura
![Page 14: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/14.jpg)
EcchymosisEcchymosis
![Page 15: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/15.jpg)
Screening tests for bleeding Screening tests for bleeding disordersdisorders
Test Abnormality detectedBlood count and Anaemia, leukaemia, DICfilm
Platelet count ThrombocytopeniaaPTT Def. of all coagulation factors except
VII, esp. follows VIII and IX; heparinPT Def. of F I, II, V, VII, and X; warfarin
Thrombin time or Hypo-, dysfibrinogenaemia; heparin fibrinogen FDPs Bleeding time Test of platelet-vessel wall interaction
![Page 16: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/16.jpg)
Causes of bleedingCauses of bleeding1 .Thrombocytopenia:
a- viral infectionsb- drug-inducedc- B12 or folate deficiencyd- ITP, DIC, TTP/HUS ( consumption)e- BM infiltration: leukemia, MM, Ca, myelofibrosis
![Page 17: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/17.jpg)
Causes..contCauses..cont..
2 .Clotting factor deficiency:
a- liver diseaseb- drugs: warfarin, heparinc- consumption: DICd- dilution: massive blood transfusione- congenital: hemophilia..etcf- vit K deficiency: e.g, malabsorption
![Page 18: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/18.jpg)
Causes…contCauses…cont..3 .CT atrophy :
a- old ageb- steroid therapyc- wasting
4 .Vessel wall disorders :A- aspirinB- Osler-Weber Rendu diseaseC- angiodysplasia
![Page 19: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/19.jpg)
ThrombocytopeniaThrombocytopeniaThe lifespan of a platelet is 7-10 days and the normal count for all ages is 150000-450000Once released from the BM young platelets are trapped in the spleen for up to 36 hours before entering the circulation, where they have a primary haemostatic role.
Congenital abnormalities of platelets can be divided into disorders of platelet production and those of platelet function. All are very rare. In general they cause moderate to severe bleeding problems.
![Page 20: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/20.jpg)
Acquired thrombocytopeniaAcquired thrombocytopeniaDecreased production of platelets due to suppression or failure of the BM is the commonest cause of thrombocytopenia. In aplastic anaemia, leukaemia and marrow infiltration, and after chemotherapy, thrombocytopenia is usually associated with a failure of red and white cell production but may be an isolated finding secondary to drug toxicity (penicillamine, cotrimoxazole), alcohol, or viralinfection (HIV, infectious mononucleosis). Viral infection is the most common cause of mild transient thrombocytopenia
![Page 21: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/21.jpg)
Acquired…contAcquired…contIncreased platelet consumption may be due to immune or non-immune mechanisms.
![Page 22: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/22.jpg)
Post-transfusion purpura (PTP) is a rare complication of blood transfusion. It presents with severe thrombocytopenia 7-10 days after the transfusion and usually occurs in multiparous women who are negative for the human platelet antigen 1a (HPA1a).Antibodies to HPA1a develop, and in some way this alloantibody is responsible for the immune destruction of autologous platelets.
![Page 23: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/23.jpg)
Neonatal alloimmune thrombocytopenia (NAITP) is similar to haemolytic disease of the newborn except that the antigenic stimulus comes from platelet specific antigens rather than redcell antigens. In 80% of cases the antigen is human platelet antigen 1a, and mothers negative (about 5% of the population) for this antigen form antibodies when sensitised by a fetus positive for the antigen. Fetal platelet destruction results from transplacental passage of these antibodies and severe bleeding, including intracranial haemorrhage, can occur in utero.
![Page 24: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/24.jpg)
Heparin-induced thrombocytopenia (HIT) occurs during unfractionated heparin therapy in up to 5% of patients, but is less frequently associated with low molecular weight heparins. It may become manifest when arterial or venous thrombosis occurs during a fall in the platelet count and is thought to be due to the formation of antibodies to heparin that are bound to platelet factor 4. The immune complexes activate platelets and endothelial cells, resulting in thrombocytopenia and thrombosis coexisting. Heparin-induced thrombocytopenia carries an appreciable mortality risk if the diagnosis is delayed.
![Page 25: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/25.jpg)
In thrombotic thrombocytopenic purpura (TTP) the presenting features can be fever, fluctuating neurological signs, renal impairment, and intravascular haemolysis, resulting in thrombocytopenia.
The condition is suspected clinically by thrombocytopenia, red cell fragmentation on the blood film, and a reticulocytosis.
![Page 26: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/26.jpg)
Causes of acquired Causes of acquired platelet dysfunctionplatelet dysfunction
•Aspirin and NSAIDs •Penicillins and cephalosporins
•Uraemia •Alcohol
•Liver disease •Myeloproliferative disorders
•Myeloma •Cardiopulmonary bypass
•Fish oils
![Page 27: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/27.jpg)
Increased consumption of Increased consumption of plateletsplatelets
•Disorders with immune mechanism:Autoimmune: ITPAlloimmune: post-transfusion purpura, neonatalalloimmune thrombocytopeniaInfection associated: infectious mononucleosis, HIV,malariaDrug induced: heparin, penicillin, quinine, rifampicin,sulphonamides
•TTP/HUS •Hypersplenism and splenomegaly
•DIC •Massive transfusion
![Page 28: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/28.jpg)
Treatment of platelet Treatment of platelet disordersdisorders
Congenital disorders:
•Platelet transfusions (leucodepleted, HLA compatible and irradiated)
•DDAVP •Tranexamic acid
•Recombinant factor VIIa •Bone marrow transplantation
![Page 29: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/29.jpg)
Treatment…contTreatment…contAcquired disorders
•Bone marrow failurePlatelet transfusions if platelet count 10000
•ITP (adults)PrednisoloneIntravenous immunoglobulinSplenectomy
•Post-transfusion purpuraIntravenous immunoglobulinPlasma exchange
•Heparin-induced thrombocytopeniaAnticoagulation but without heparin
•Thrombotic thrombocytopenic purpuraLarge volume plasma exchangeAspirin when platelets 50000
![Page 30: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/30.jpg)
Treatment…contTreatment…cont •DIC:
Treat underlying causeFresh frozen plasmaPlatelet transfusion
•HypersplenismSplenectomy if severe
•Platelet function disordersPlatelet transfusionDDAVP
![Page 31: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/31.jpg)
Idiopathic thrombocytopenic Idiopathic thrombocytopenic purpura(ITP)purpura(ITP)
It is due to auto- antibodies directed against PLT membrane glycoprotein IIb-IIIa which causes premature removal of PLTs by the monocyte-macrophage systemASSOCIATIONS—neoplasm (CLL, lymphoma), infections (HIV), autoimmune (SLE)
![Page 32: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/32.jpg)
ITPITPC/F: 1. in children: sudden onset of purpura, oral or nasal bleeding, usually 2-3 wk after a viral illness
2 .In adults: affects females more, with insidious onset, usually not associated with viral infection.
It is characterised by remission and relapse.
![Page 33: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/33.jpg)
ITPITPLAB.
1 .CBC: reduced PLT count2 .BM: increased megakaryocytes
![Page 34: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/34.jpg)
managementmanagement1 .In children: usually it is self-limiting,
if severe purpura or epistaxis, or PLT <10000 give steroids ( prednisolone 2mg/kg/d)If pesistent epistaxis GI bleeding, retinal hemorrhage : give PLT transfusion and IV IgG
![Page 35: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/35.jpg)
managementmanagement2 .In adults: prednisolone 1 mg/kg/d for 3-4 wk then
gradually tapered over 6-8 wk, relapse may occur on tapering. Platelet recovery occurs within 3 weeks in 2/3 of pts. If platelet count did not increase after 4 weeks of treatment, consider splenectomyPLT transfusion and IVIg 1 g/kg IV daily 1–2 days, indicated in life-threatening bleeding. If the pt has two relapses , splenectomy is indicated, which is curative in 70% of patients, in the remainder the aim is to keep the patient free of symptoms rather than to raise level of PLT( e.g 5mg/d of prednisolone may be sufficient)
![Page 36: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/36.jpg)
managementmanagementIn severe cases iv methylpredinsolone 1gIV dailyX3 days. with or without IVIg may be givenIf still not controlled give immunosuppressive drugs e.g: vincristine, cyclophosphamide
![Page 37: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/37.jpg)
Hemophilia AHemophilia AFactor VIII is synthesized mainly by liver , but also by spleen, kidney, and placenta, carried by vWF, half-life in plasma is 12hr.
It is X-linked recessive and affects about 1/10000, thus all daughters of hemophiliacs are carriers and 50% of sisters are carriers. If a carrier has a son, he has 50% chance of having hemophilia and a daughter has 50% chance of being a carrier
![Page 38: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/38.jpg)
Hemophilia AHemophilia AC/FAt around 6 mon. child develop bruises and hemarthrosis as he starts to move around.
Normal level of factor VIII is 50%-150%, and severity is measured according to this level:
1 .severe: <1% F VIII or IX: liable for spontaneous hemarthrosis & muscle hematoma
![Page 39: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/39.jpg)
Hemophilia AHemophilia A2 .Moderate : 1-5% F VIII or IX: mild
trauma or surgery causes hematoma3 .mild: 6-50% F VIII or IX: major
surgery or injury results in excess bleeding.Joints commonly affected include: knees, elbows, ankles, and hips.They look hot, swollen, and very painfull and tender.
![Page 40: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/40.jpg)
Hemophilia AHemophilia AWith recurrent bleeding there will be synovial hypertrophy, destruction of cartilage and secondary osteoarthritis,In muscles : calf, psoas: bleeding lead to ischemia, necrosis, fibrosis which will lead to contracture & shortening of tendons e.g achilles tendon making walking difficult.
![Page 41: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/41.jpg)
Shortening of Achilles Shortening of Achilles tendontendon
![Page 42: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/42.jpg)
Dosing guidelines for hemophilia ADosing guidelines for hemophilia AMild bleeding :
Target: 30% dosing q8-12h; 1-2 days (15U/kg)Hemarthrosis, oropharyngeal or dental, epistaxis, hematuria
Major bleeding:Target: 80-100% q8-12h; 7-14 days (50U/kg)CNS trauma, hemorrhage, lumbar punctureSurgeryRetroperitoneal hemorrhageGI bleeding
Adjunctive therapy : -aminocaproic acid or DDAVP (for mild disease only)
![Page 43: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/43.jpg)
Von Willebrand’s diseaseVon Willebrand’s diseaseUsually it is a mild bleeding disorder of many types, the commonest being type I which is autosomal dominant.
vWF is synthesized by endothelial cells and megakaryocytes and has two functions: 1. carrier for F VIII
2 .form bridges between PLT and subendothelial collagen
![Page 44: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/44.jpg)
vW DisvW Dis..
C/FBruising, epistaxis, menorrhagia, GI bleedingLAB
*Decreased level of vWF, increased bleeding time, increased PTT
![Page 45: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/45.jpg)
Treatment of von Willebrand DiseaseTreatment of von Willebrand Disease
Cryoprecipitate Source of fibrinogen, factor VIII and VWF
DDAVP (deamino-8-arginine vasopressin) plasma VWF levels by stimulating secretion from
endothelium
Not generally used in type 2 disease Dosage 0.3 µg/kg q 12 hr IV
Factor VIII concentrate Virally inactivated product
![Page 46: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/46.jpg)
Common clinical conditions associated Common clinical conditions associated with DICwith DIC
Sepsis (Escherichia coli,
N. meningitidis, malaria(
Trauma: Head injury, Fat embolism
Malignancy lung,prostate,pancreatic
Obstetrical complications:
Amniotic fluid embolismAbruptio placentae
Vascular disorders
Reaction to toxin (e.g. snake venom, drugs)
Immunologic disordersSevere allergic reactionTransplant rejection
Activation of both coagulation and fibrinolysisTriggered by
![Page 47: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/47.jpg)
PathophysiologyPathophysiologydamage to endothelium →release of tissue factor → massive activation ofcoagulation cascade → intravascular coagulation and depletion of clotting factors
![Page 48: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/48.jpg)
FeaturesFeaturesmicroangiopathic hemolytic anemia, thrombocytopenia, bleeding, thrombosis, ischemia. ↑INR, ↑ PTT, ↓ fibrinogen (although it can be normal or even elevated), ↓ factor VIII (in contrast to liver diseases, which have normal factor VIII). Schistocytes on peripheral smear
![Page 49: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/49.jpg)
TreatmentTreatmenttreat underlying cause and complications (hypoxia, dehydration, acidosis, acute renal failure). Replete coagulation factors if bleeding (FFP 2 U, cryoprecipitate 10 U). Anticoagulation if thrombosis (consider IV heparin)
![Page 50: medicine.Bleeding disorders.(dr.sabir) (new powerpoint)](https://reader035.fdocuments.in/reader035/viewer/2022062702/554afbbcb4c90559058b5035/html5/thumbnails/50.jpg)
Management of Hemostatic Management of Hemostatic Defects in Liver DiseaseDefects in Liver Disease
Treatment for prolonged PT/PT Vitamin K 10 mg x 3 days - usually ineffective
Fresh-frozen plasma infusion (1200-1500 ml) immediate but temporary effect
Treatment for low fibrinogen Cryoprecipitate (1 unit/10kg body weight)
Treatment for DIC Replacement therapy